Dissemin is shutting down on January 1st, 2025

Published in

Springer (part of Springer Nature), Acta Neuropathologica, 3(127), p. 407-418

DOI: 10.1007/s00401-013-1239-x

Links

Tools

Export citation

Search in Google Scholar

TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions

Journal article published in 2014 by Jc C. Van Swieten, Sb B. Wharton, Michael D. School of Medicine University of Pennsylvania Philadelphia Gallagher, Eunran Center for Neurodegenerative Disease Research Perelman School of Medicine University of Pennsylvania Philadelphia PA Suh, Cl L. White, Murray Department of Neurology Perelman School of Medicine University of Pennsylvania Grossman, Rl L. Woltjer, Lauren Department of Neurology Perelman School of Medicine University of Pennsylvania Elman, Leo Department of Neurology Perelman School of Medicine University of Pennsylvania McCluskey, Safa King’s College Hospital London UK Al-Sarraj, Manuela Claudia Neumann, Jonathan D. Dementia Research Centre Department of Neurodegenerative Disease UCL Institute of Neurology London UK Rohrer, Glenda Neuroscience Research Australia Faculty of Medicine UNSW Halliday, Ellen Neurological Tissue Bank of the Biobank-Hospital Clinic-Insitut d’Investigacions Biomèdiques August Pi I. Sunyer Facultad de Medicin Gelpi, Pj J. Shaw and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Hexanucleotide repeat expansions in chromosome 9 open reading frame 72 (C9orf72) have recently been linked to frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis, and may be the most common genetic cause of both neurodegenerative diseases. Genetic variants at TMEM106B influence risk for the most common neuropathological subtype of FTLD, characterized by inclusions of TAR DNA-binding protein of 43 kDa (FTLD-TDP). Previous reports have shown that TMEM106B is a genetic modifier of FTLD-TDP caused by progranulin (GRN) mutations, with the major (risk) allele of rs1990622 associating with earlier age at onset of disease. Here, we report that rs1990622 genotype affects age at death in a single-site discovery cohort of FTLD patients with C9orf72 expansions (n = 14), with the major allele correlated with later age at death (p = 0.024). We replicate this modifier effect in a 30-site international neuropathological cohort of FTLD-TDP patients with C9orf72 expansions (n = 75), again finding that the major allele associates with later age at death (p = 0.016), as well as later age at onset (p = 0.019). In contrast, TMEM106B genotype does not affect age at onset or death in 241 FTLD-TDP cases negative for GRN mutations or C9orf72 expansions. Thus, TMEM106B is a genetic modifier of FTLD with C9orf72 expansions. Intriguingly, the genotype that confers increased risk for developing FTLD-TDP (major, or T, allele of rs1990622) is associated with later age at onset and death in C9orf72 expansion carriers, providing an example of sign epistasis in human neurodegenerative disease.